Original Research

Published on 13 Dec 2021

PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC： A Cost-Effectiveness Analysis in China

in Thoracic Oncology

Qiao Liu
Xia Luo
Zhen Zhou
Liubao Peng
Lidan Yi
Xiaomin Wan
Chongqing Tan
Xiaohui Zeng

Frontiers in Oncology

doi 10.3389/fonc.2021.745493

3,054 views
3 citations

Original Research

Published on 13 Dec 2021

A Nomogram for Predicting Brain Metastasis in IIIA-N2 Non-Small Cell Lung Cancer After Complete Resection: A Competing Risk Analysis

in Thoracic Oncology

Shuang Sun
Yu Men
Jingjing Kang
Xin Sun
Meng Yuan
Xu Yang
Yongxing Bao
Jianyang Wang
Lei Deng
Wenqing Wang

Frontiers in Oncology

doi 10.3389/fonc.2021.781340

2,473 views
4 citations

Original Research

Published on 10 Dec 2021

CT-Based Radiomics Nomogram for Differentiation of Anterior Mediastinal Thymic Cyst From Thymic Epithelial Tumor

in Thoracic Oncology

Chengzhou Zhang
Qinglin Yang
Fan Lin
Heng Ma
Haicheng Zhang
Ran Zhang
Ping Wang
Ning Mao

Frontiers in Oncology

doi 10.3389/fonc.2021.744021

2,814 views
4 citations

Original Research

Published on 10 Dec 2021

Survival of Black and White Patients With Stage IV Small Cell Lung Cancer

in Thoracic Oncology

Huashan Shi
Kexun Zhou
Jordan Cochuyt
David Hodge
Hong Qin
Rami Manochakian
Yujie Zhao
Sikander Ailawadhi
Alex A. Adjei
Yanyan Lou

Frontiers in Oncology

doi 10.3389/fonc.2021.773958

4,989 views
2 citations

Original Research

Published on 09 Dec 2021

Overexpression of Reactive Oxygen Species Modulator 1 Predicts Unfavorable Clinical Outcome in EGFR-Mutant Lung Adenocarcinomas Treated With Targeted Therapy

in Thoracic Oncology

Won Gun Kwack
Ji-Youn Sung
Seung Hyeun Lee

Frontiers in Oncology

doi 10.3389/fonc.2021.770230

1,479 views
2 citations

Original Research

Published on 09 Dec 2021

Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer

in Thoracic Oncology

Szu-Chun Yang
Natalia Kunst
Cary P. Gross
Jung-Der Wang
Wu-Chou Su
Shi-Yi Wang

Frontiers in Oncology

doi 10.3389/fonc.2021.760686

5,234 views
8 citations

Original Research

Published on 09 Dec 2021

Lobectomy Versus Sublobectomy in Stage IIIA/N2 Non-Small Cell Lung Cancer: A Population-Based Study

in Thoracic Oncology

Suyu Wang
Zhiyuan Zhang
Yang Gu
Xin Lv
Xuan Shi
Meiyun Liu

Frontiers in Oncology

doi 10.3389/fonc.2021.726811

3,273 views
2 citations

Original Research

Published on 08 Dec 2021

Aurora Kinase A as a Diagnostic and Prognostic Marker of Malignant Mesothelioma

in Thoracic Oncology

Zhenying Guo
Li Shen
Ningning Li
Xiaoxiao Wu
Canming Wang
Zheng Gu
Zhongjian Chen
Junping Liu
Weimin Mao
Yuchen Han

Frontiers in Oncology

doi 10.3389/fonc.2021.789244

3,707 views
5 citations

Original Research

Published on 07 Dec 2021

Development and Validation of a Scoring System for Early Diagnosis of Malignant Pleural Effusion Based on a Nomogram

in Thoracic Oncology

Aihua Wu
Zhigang Liang
Songbo Yuan
Shanshan Wang
Weidong Peng
Yijun Mo
Jing Yang
Yanqing Liu

Frontiers in Oncology

doi 10.3389/fonc.2021.775079

2,739 views
8 citations

Review

Published on 01 Dec 2021

Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR

in Thoracic Oncology

Karan Seegobin
Umair Majeed
Nathaniel Wiest
Rami Manochakian
Yanyan Lou
Yujie Zhao

Frontiers in Oncology

doi 10.3389/fonc.2021.750657

13,884 views
40 citations

Original Research

Published on 01 Dec 2021

Efficacy of Intraoperative Hypertonic Glucose Solution Administration on Persistent Air Leak After Extended Pleurectomy/Decortication for Malignant Pleural Mesothelioma: A Retrospective Case–Control Study

in Thoracic Oncology

Alberto Testori
Gianluca Perroni
Marco Alloisio
Emanuele Voulaz
Veronica Maria Giudici
Umberto Cariboni
Edoardo Bottoni

Frontiers in Oncology

doi 10.3389/fonc.2021.767791

1,909 views
2 citations

Original Research

Published on 30 Nov 2021

The Prognostic Role of Blood Inflammatory Biomarkers and EGFR Mutation Status in Stage IIIA/N2 Non-Small Cell Lung Cancer Patients Treated With Trimodality Therapy

in Thoracic Oncology

Hui Yang
Kunlun Wang
Bingxu Li
Shenglei Li
Yan Li
Ling Yuan

Frontiers in Oncology

doi 10.3389/fonc.2021.707041

2,466 views
10 citations

Original Research

Published on 30 Nov 2021

NFAT as a Biomarker and Therapeutic Target in Non–Small Cell Lung Cancer–Related Brain Metastasis

in Thoracic Oncology

Lu Peng
Yihao Tao
Rui Wu
Jing Su
Maoyuan Sun
Yuan Cheng
Zongyi Xie
Jinning Mao
Xiaohui Zhan
Guodong Liu

Frontiers in Oncology

doi 10.3389/fonc.2021.781150

4,244 views
6 citations

Original Research

Published on 26 Nov 2021

Cost-Effectiveness Analysis of Pembrolizumab Plus Pemetrexed and Platinum Versus Chemotherapy Alone as First-Line Treatment in Metastatic Non-Squamous Non–Small Cell Lung Cancer: A Reconstruction of Partitioned Survival Model Based on Time Dependent Pricing Mechanism of Patient Assistance Program

in Thoracic Oncology

Yuanyi Cai
Wen Hui
Min Zhu
Mingyue Zhang
Zhixiang Gao
Huazhang Wu

Frontiers in Oncology

doi 10.3389/fonc.2021.768035

5,115 views
7 citations

Review

Published on 25 Nov 2021

Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China

in Thoracic Oncology

Anwen Xiong
Jiali Wang
Caicun Zhou

Frontiers in Oncology

doi 10.3389/fonc.2021.757993

8,107 views
26 citations

Editorial

Published on 23 Nov 2021

Editorial: New Trends in Early-Stage Lung Cancer Presenting as Ground-Glass Opacities: Clinical, Pathological and Molecular Aspects

in Thoracic Oncology

Kezhong Chen
Chen Chen

Frontiers in Oncology

doi 10.3389/fonc.2021.792252

1,470 views

Navigation group

Articles

PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC： A Cost-Effectiveness Analysis in China

A Nomogram for Predicting Brain Metastasis in IIIA-N2 Non-Small Cell Lung Cancer After Complete Resection: A Competing Risk Analysis

CT-Based Radiomics Nomogram for Differentiation of Anterior Mediastinal Thymic Cyst From Thymic Epithelial Tumor

Survival of Black and White Patients With Stage IV Small Cell Lung Cancer

Overexpression of Reactive Oxygen Species Modulator 1 Predicts Unfavorable Clinical Outcome in EGFR-Mutant Lung Adenocarcinomas Treated With Targeted Therapy

Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer

Lobectomy Versus Sublobectomy in Stage IIIA/N2 Non-Small Cell Lung Cancer: A Population-Based Study

Aurora Kinase A as a Diagnostic and Prognostic Marker of Malignant Mesothelioma

Development and Validation of a Scoring System for Early Diagnosis of Malignant Pleural Effusion Based on a Nomogram

Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR

Efficacy of Intraoperative Hypertonic Glucose Solution Administration on Persistent Air Leak After Extended Pleurectomy/Decortication for Malignant Pleural Mesothelioma: A Retrospective Case–Control Study

The Prognostic Role of Blood Inflammatory Biomarkers and EGFR Mutation Status in Stage IIIA/N2 Non-Small Cell Lung Cancer Patients Treated With Trimodality Therapy

NFAT as a Biomarker and Therapeutic Target in Non–Small Cell Lung Cancer–Related Brain Metastasis

Cost-Effectiveness Analysis of Pembrolizumab Plus Pemetrexed and Platinum Versus Chemotherapy Alone as First-Line Treatment in Metastatic Non-Squamous Non–Small Cell Lung Cancer: A Reconstruction of Partitioned Survival Model Based on Time Dependent Pricing Mechanism of Patient Assistance Program

Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China

Editorial: New Trends in Early-Stage Lung Cancer Presenting as Ground-Glass Opacities: Clinical, Pathological and Molecular Aspects